The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use 0.25µg for 105-8 cells. Use a final volume of 100µl.
ab18436-Mouse monoclonal IgG3, is suitable for use as an isotype control with this antibody.
The CD3 complex mediates signal transduction.
Involvement in disease
Defects in CD3D are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)/B(+)/NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Staining of rat splenocytes with anti-CD45R FITC and staining buffer (autofluorescence) (left) or 0.125µg of ab95508 (right) followed by Streptavidin PE. Cells in the lymphocyte gate were used for analysis.
References for Anti-CD3 antibody [G4.18] (Biotin) (ab95508)
This product has been referenced in:
Tran GT et al. Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAb therapy with a preferential effect on T(h)1 cells that is augmented by IL-4. Int Immunol13:1109-20 (2001).
Read more (PubMed: 11526091) »
Nicolls MR et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation55:459-68 (1993).
Read more (PubMed: 8456460) »